Literature DB >> 17011009

Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV.

Vanessa Rivera-Amill1, Richard J Noel, Suheydi Orsini, Griselle Tirado, José M García, Shilpa Buch, Anil Kumar.   

Abstract

We analyzed the association between the evolution of the V3-V5 regions of env and disease progression in our SIV/SHIV macaque model of morphine dependence and AIDS. Previous studies revealed two distinct disease patterns--fast progression and normal progression. To determine the effect of the two distinct patterns of disease in the evolution of SIV/17E-Fr envelope, we analyzed env sequences from three morphine-dependent macaques that developed accelerated AIDS and three morphine-dependent macaques that developed AIDS at a slower rate and compared them to control macaques. Morphine-dependent animals exhibited a higher percentage of diversity in both plasma and CSF compartments within V4 when compared to controls. Divergence from the inoculum was significantly greater in the morphine group as compared to controls in CSF but not in plasma. We also found a direct correlation in V4 evolution and rapid disease progression. These results indicate that morphine dependence plays a role in the pathogenesis of SIV/SHIV infection and env evolution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011009      PMCID: PMC3188391          DOI: 10.1016/j.virol.2006.08.039

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

Review 1.  The development of animal model systems for HIV-1 encephalitis and its associated dementia.

Authors:  Y Persidsky; H S Nottet; V G Sasseville; L G Epstein; H E Gendelman
Journal:  J Neurovirol       Date:  1995-09       Impact factor: 2.643

Review 2.  Injection drug use and HIV/AIDS transmission in China.

Authors:  Tian Xin Chu; Judith A Levy
Journal:  Cell Res       Date:  2005 Nov-Dec       Impact factor: 25.617

Review 3.  Animal models for development of an AIDS vaccine.

Authors:  M B Gardner
Journal:  Int Rev Immunol       Date:  1990       Impact factor: 5.311

4.  Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor.

Authors:  Chang-Jiang Guo; Yuan Li; Sha Tian; Xu Wang; Steven D Douglas; Wen-Zhe Ho
Journal:  J Investig Med       Date:  2002-11       Impact factor: 2.895

5.  An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.

Authors:  Xinping Ren; Joseph Sodroski; Xinzhen Yang
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Virus replication and disease progression inversely correlate with SIV tat evolution in morphine-dependent and SIV/SHIV-infected Indian rhesus macaques.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2005-11-28       Impact factor: 3.616

Review 7.  Injection drug use and human immunodeficiency virus infection.

Authors:  P Alcabes; G Friedland
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

8.  Morphine enhances HIV infection of neonatal macrophages.

Authors:  Yuan Li; Jeffrey D Merrill; Kathy Mooney; Li Song; Xu Wang; Chang-Jiang Guo; Rashmin C Savani; David S Metzger; Steven D Douglas; Wen-Zhe Ho
Journal:  Pediatr Res       Date:  2003-05-07       Impact factor: 3.756

9.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Injection drug use and HIV/AIDS in China: review of current situation, prevention and policy implications.

Authors:  Han-Zhu Qian; Joseph E Schumacher; Huey T Chen; Yu-Hua Ruan
Journal:  Harm Reduct J       Date:  2006-02-01
View more
  9 in total

1.  Identification and molecular characterization of SIV Vpr R50G mutation associated with long term survival in SIV-infected morphine dependent and control macaques.

Authors:  Ivelisse Rivera; Yashira García; Mohitkumar R Gangwani; Richard J Noel; Lucianette Maldonado; Anil Kumar; Vanessa Rivera-Amill
Journal:  Virology       Date:  2013-08-28       Impact factor: 3.616

Review 2.  Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution.

Authors:  Vanessa Rivera-Amill; Peter S Silverstein; Richard J Noel; Santosh Kumar; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-16       Impact factor: 4.147

Review 3.  Opiates, immune system, acquired immunodeficiency syndrome, and nonhuman primate model.

Authors:  Richard J Noel; Vanessa Rivera-Amill; Shilpa Buch; Anil Kumar
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

4.  Analysis of the V1V2 region of the SIV envelope in the brains of morphine-dependent and control SIV/SHIV-infected macaques.

Authors:  Vanessa Rivera-Amill; Richard J Noel; Ivelisse Rivera Román; Yashira García Flores; Shilpa Buch; Anil Kumar
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

5.  Accelerated evolution of SIV env within the cerebral compartment in the setting of morphine-dependent rapid disease progression.

Authors:  Vanessa Rivera-Amill; Richard J Noel; Yashira García; Ivelisse Rivera; Marcus Iszard; Shilpa Buch; Anil Kumar
Journal:  Virology       Date:  2009-12-30       Impact factor: 3.616

Review 6.  Opiate drug use and the pathophysiology of neuroAIDS.

Authors:  Kurt F Hauser; Sylvia Fitting; Seth M Dever; Elizabeth M Podhaizer; Pamela E Knapp
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

7.  NF-κB Duplications in the Promoter-Variant HIV-1C LTR Impact Inflammation Without Altering Viral Replication in the Context of Simian Human Immunodeficiency Viruses and Opioid-Exposure.

Authors:  Rajnish S Dave; Haider Ali; Susmita Sil; Lindsey A Knight; Kabita Pandey; Lepakshe S V Madduri; Fang Qiu; Udaykumar Ranga; Shilpa Buch; Siddappa N Byrareddy
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

8.  Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.

Authors:  Yan Li; Dan Yang; Jia-Ye Wang; Yuan Yao; Wei-Zhe Zhang; Lu-Jing Wang; De-Chun Cheng; Feng-Kun Yang; Feng-Min Zhang; Min Zhuang; Hong Ling
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

Review 9.  Opioid and neuroHIV Comorbidity - Current and Future Perspectives.

Authors:  Sylvia Fitting; MaryPeace McRae; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-02       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.